Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Homburg, R.
Right arrow Articles by Ben-Rafae, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Homburg, R.
Right arrow Articles by Ben-Rafae, Z.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 10, No. 10, pp. 2550-2553, 1995
© 1995 European Society of Human Reproduction and Embryology

research-article

Adjuvant growth hormone for induction of ovulation with gonadotrophin-releasing hormone agonist and gonadotrophins in polycystic ovary syndrome: a randomized, double-blind, placebo controlled trial

Roy Homburg1, Tally Levy and Zion Ben-Rafae

Infertility Unit, Golda Medical Center Petah Tikva 49372, Israel. Affiliated to Sackler Medical School Tel Aviv University, Israel

Correspondence: 1To whom correspondence should be addressed

The objective of this study was to explore the effect of cotreatment with recombinant human growth hormone (GH), gonadotrophin-releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG) for induction of ovulation in women with clomiphene resistant polycystic ovary syndrome (PCOS). It was designed as a randomized, double-blind, placebo controlled trial in which 30 women with anovulation associated with PCOS who were resistant to clomiphene all received DTRP6-LHRH (Decapeptyl microcapsules, 3.75 mg, i.m.) and, 2 weeks later, HMG in a standard, conventional, individually adjusted dose regimen until human chorionic gonadotrophin (HCG) and then luteal phase support could be given. From day 1 of HMG therapy, patients were randomized to receive either human GH (Norditropin, 12 IU/day, i.m., for 7 days) or placebo. The number of ampoules, duration of treatment and daily effective dose of HMG required to achieve ovulation, serum oestradiol concentrations and number of follicles induced, ovulation and pregnancy rates, serum insulin and insulin-like growth factor-I (IGF-I) concentrations were measured. There were no significant differences between growth hormone and placebo groups in any of the outcomes measured, other than a growth hormone induced increase in serum insulin and IGF-I levels. We conclude that although GH kinetics are abnormal and GH pituitary reserves generally low in women with PCOS, adjuvant GH treatment to GnRHa/HMG does not influence follicular development or sensitivity in response to gonadotrophins and that it does not seem likely to be of any potential clinical benefit for the treatment of PCOS.

Key words: GnRHa/growth factors/growth hormone/HMG/ovulation induction/PCOS


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
J. Tesarik, A. Hazout, and C. Mendoza
Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone
Hum. Reprod., September 1, 2005; 20(9): 2536 - 2541.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S.D. Keay, N.H. Liversedge, V.A. Akande, R.S. Mathur, and J.M. Jenkins
Serum IGF-1 concentrations following pituitary desensitization do not predict the ovarian response to gonadotrophin stimulation prior to IVF
Hum. Reprod., September 1, 2003; 18(9): 1797 - 1801.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. W. C. M. van Dam, F. Roelfsema, F. H. Helmerhorst, M. Frolich, A. E. Meinders, J. D. Veldhuis, and H. Pijl
Low Amplitude and Disorderly Spontaneous Growth Hormone Release in Obese Women with or without Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4225 - 4230.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
Th. Kaltsas, N. Pontikides, G.E. Krassas, K. Seferiadis, D. Lolis, and I.E. Messinis
Growth hormone response to thyrotrophin releasing hormone in women with polycystic ovarian syndrome
Hum. Reprod., November 1, 1999; 14(11): 2704 - 2708.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice
The Insulin-Related Ovarian Regulatory System in Health and Disease
Endocr. Rev., August 1, 1999; 20(4): 535 - 582.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. A. M. de Boer, M. van der Meer, E. A. van der Veen, and J. Schoemaker
Growth Hormone (GH) Substitution in Hypogonadotropic, GH-Deficient Women Decreases the Follicle-Stimulating Hormone Threshold for Monofollicular Growth
J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 590 - 595.
[Abstract] [Full Text]

Home page
 Hum ReprodHome page
R. Homburg and I. E. Messinis
Growth hormone kinetics in polycystic ovary syndrome
Hum. Reprod., January 1, 1999; 14(1): 271 - 271.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.